Tango Therapeutics (TNGX) announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. Sung Lee currently serves as Executive Vice President and CFO at Cytokinetics (CYTK).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics Adds Independent Director to Strengthen Governance
- Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat
- Tango Therapeutics initiated with a Buy at Stifel
- Tango Therapeutics Enters New Sales Agreement with Leerink
- Tango Therapeutics files to sell 1.73M shares of common stock for holders